Year in cancer

2003 in cancer

What the index holds for 2003: regulatory decisions dated that year, studies first posted that year, PubMed output per cancer for that year and the registry observations whose reference year it is. Every figure is a count of dated source records — nothing is estimated.

Regulatory

Approval records dated 2003 (46)

Approved, accelerated or conditional records by authority; original applications and records naming one cancer are listed first. One record is one decision for one application or product identifier.

FDA · US: 39 records / 16 drugsHealth Canada · CA: 7 records / 5 drugs

May 13, 2003Bortezomib FDA · US original application approved Mantle Cell Lymphomatreatment of adult patients with mantle cell lymphomaopenfda
May 13, 2003Bortezomib FDA · US original application approved Multiple Myelomatreatment of adult patients with multiple myelomaopenfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Acute Lymphoblastic LeukemiaAdult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).openfda
Apr 18, 2003Imatinib FDA · US original application approved Acute Lymphoblastic LeukemiaAdult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Myelodysplastic/Myeloproliferative NeoplasmAdult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Aggressive Systemic MastocytosisAdult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.openfda
Apr 18, 2003Imatinib FDA · US original application approved Acute Lymphoblastic LeukemiaPediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.openfda
Apr 18, 2003Imatinib FDA · US original application approved Myelodysplastic/Myeloproliferative NeoplasmAdult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.openfda
Apr 18, 2003Imatinib FDA · US original application approved Aggressive Systemic MastocytosisAdult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Acute Lymphoblastic LeukemiaPediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Malignant Gastrointestinal Stromal TumorPatients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).openfda
Apr 18, 2003Imatinib FDA · US original application approved Malignant Gastrointestinal Stromal TumorPatients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).openfda
Apr 18, 2003Imatinib FDA · US original application approved Chronic Eosinophilic Leukemia, Not Otherwise SpecifiedAdult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis…openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved Chronic Eosinophilic Leukemia, Not Otherwise SpecifiedAdult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis…openfda
Feb 13, 2003Leuprolide FDA · US original application approved Malignant Prostate NeoplasmVABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of…openfda
Sep 11, 2003Metformin FDA · US original application approved cancer not stated in this recordRIOMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2…openfda
Apr 18, 2003Imatinib Mesylate FDA · US original application approved cancer not stated in this recordNewly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Patients with…openfda
Apr 18, 2003Imatinib FDA · US original application approved cancer not stated in this recordNewly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Patients with…openfda
Dec 24, 2003Fulvestrant FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-12-24 (see label)openfda
Dec 17, 2003Gefitinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as IRESSA (DIN 02248676) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Dec 8, 2003Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-12-08 (see label)openfda
Dec 8, 2003Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-12-08 (see label)openfda
Dec 1, 2003Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ELIGARD (DIN 02248240) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Dec 1, 2003Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ELIGARD (DIN 02248239) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Nov 18, 2003Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241799) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
Nov 3, 2003Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241800) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
Oct 22, 2003Hydroxyurea Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as APO-HYDROXYUREA (DIN 02247937) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
Sep 16, 2003Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-09-16 (see label)openfda
Sep 16, 2003Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-09-16 (see label)openfda
Aug 14, 2003Peginterferon Alfa-2a Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PEGASYS (DIN 02248077) under ATC L03AB11 PEGINTERFERON ALFA-2A. Indications are not published in the Drug Product Database — see the…health-canada-dpd
Jun 26, 2003Hydroxyurea FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-06-26 (see label)openfda
May 20, 2003Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-05-20 (see label)openfda
May 20, 2003Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-05-20 (see label)openfda
May 8, 2003Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-05-08 (see label)openfda
May 2, 2003Interferon Beta-1a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-05-02 (see label)openfda
Apr 11, 2003Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-04-11 (see label)openfda
Apr 11, 2003Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-04-11 (see label)openfda
Mar 14, 2003Interferon Beta-1b FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-03-14 (see label)openfda
Mar 11, 2003Temozolomide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-03-11 (see label)openfda
Feb 26, 2003Topotecan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-02-26 (see label)openfda
Feb 26, 2003Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-02-26 (see label)openfda
Feb 25, 2003Carmustine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-02-25 (see label)openfda
Feb 7, 2003Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-02-07 (see label)openfda
Feb 7, 2003Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-02-07 (see label)openfda
Jan 31, 2003Interferon Beta-1a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-01-31 (see label)openfda
Jan 17, 2003Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2003-01-17 (see label)openfda

RegulatoryAll 2003 records with filters →

Clinical research

Studies first posted in 2003

ClinicalTrials.gov oncology studies whose first-posted date falls in the year (all study types unless stated). Cancer attribution uses reconciled conditions over descendants; one study can count for several top-level cancers.

Studies: 2,669
Interventional: 2,609
Phase III: 539
Industry-led: 304
With posted results: 346
Countries with sites: 79

By phase (a study with two phases counts in both)
Phase	Studies	Interventional	Industry share
Early Phase 1	2	2	0%
Phase 1	737	737	13%
Phase 2	1,445	1,445	13%
Phase 3	539	539	12%
Phase 4	8	8	63%
Not applicable / not stated	172	112	2%

Top-level cancers by studies (descendants included)
Cancer	Studies	Phase III
Leukemia	329	52
Malignant Breast Neoplasm	286	86
Malignant Lung Neoplasm	252	53
Malignant Prostate Neoplasm	163	42
Malignant Ovarian Neoplasm	146	19
Non-Hodgkin Lymphoma	113	11
Malignant Kidney Neoplasm	87	14
Malignant Pancreatic Neoplasm	76	14
Malignant Cervical Neoplasm	72	11
Malignant Liver Neoplasm	57	6
Malignant Central Nervous System Neoplasm	56	2
Malignant Bladder Neoplasm	55	15

Lead sponsors of interventional studies first posted in 2003
Lead sponsor	Class	Studies	Phase III
National Cancer Institute (NCI)	Nih	466	40
Memorial Sloan Kettering Cancer Center	Other	138	5
Alliance for Clinical Trials in Oncology	Other	122	37
European Organisation for Research and Treatment of Cancer - EORTC	Network	116	65
SWOG Cancer Research Network	Network	81	25
Children's Oncology Group	Network	68	26
Eastern Cooperative Oncology Group	Network	66	19
Gynecologic Oncology Group	Network	61	17
Burzynski Research Institute	Other	59	0
Radiation Therapy Oncology Group	Network	56	24

Published source: clinicaltrials · first_posted_date as posted

Research output

PubMed records, 2003

Records matching each top-level cancer's stored PubMed query with a publication year equal to this year, with the previous year for comparison. A count of indexed records, not of scientific impact.

No literature window for 2003

Yearly PubMed windows are computed from 2016 onwards for entities with a stored query.

Registries

Observations with reference year 2003

What registries have published for this year: observations by source, metric and geography. Registries publish with a lag of one to three years.

Geography	Metric	Source	Observations	Cancers
United States	Incidence rate (age-standardized)	cdc-uscs	80	32
United States	Mortality rate (age-standardized)	cdc-uscs	77	31
United States	New cases	cdc-uscs	88	32
United States	Deaths	cdc-uscs	85	31

Open 2003 in the Data explorer →